News and Updates
iVeena receives Notice of Allowance from the US Patent Office for patent protecting cataract implants (IVMED 10&20).
Salt Lake City, Utah,--(BUSINESS WIRE)--iVeena Delivery Systems (iVeena), a biopharmaceutical company that develops innovative ophthalmology products, today announced that the United States Patent and...
iVeena Receives FDA Orphan Drug Designation for IVMED-80 for the Treatment of Keratoconus
iVeena announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for IVMED-80, for the treatment of keratoconus. Keratoconus is a degenerative disorder causing a c...
iVeena Completes Phase I/2a Pilot Clinical Study of IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant to Treat Inflammation and Pain Associated with Cataract Surgery
iVeena Completes Phase 1/2a Pilot Clinical Study for IVMED-10, a Bioerodable, Sustained Release, Intracapsular Implant that Delivers Dexamethasone to Both Anterior and Posterior Eye Segments to Treat...
iVeena has been awarded a total of $450K in NSF and NIH grants to advance its Keratoconus Orphan Drug candidate and Gene Therapy programs.
"iVeena is pleased to receive a total of $450K in Federal Government grants to advance its portfolio programs," said Gerald Simmons, CEO. "$225K is an NIH grant for its Keratoconus Orphan Drug candida...
iVeena announces the initiation of its Phase I/2b in-human pilot clinical study for IVMED-10, a bioerodable implant designed to eliminate the need for eye drops after cataract surgery.
On Monday, May 30th, iVeena initiated the Phase I/2a pilot clinical study for IVMED-10. This product is a bioerodable dexamethasone implant given at the time of cataract surgery that releases the drug...
Page 5 of 9